Abstract |
Lysine acetylation plays a critical role in cellular regulation and is implicated in human disease. Sirtuin deacetylases remove acetyl groups from modified lysine residues, and sirtuin 3 ( SIRT3) has been identified as a target for cancer therapeutics. Robust and high-throughput screening methods for these targets will be important to the development of therapeutics. This article describes the use of self-assembled monolayer desorption/ionization mass spectrometry, or SAMDI-MS-a label-free drug discovery tool--to characterize SIRT3 activity and discover inhibitors. SAMDI-MS was used to analyze a peptide array having 361 distinct acetylated peptides to identify an active SIRT3 substrate (GYK(Ac)RGC). This peptide was used in a screen of 100,000 small molecules to identify inhibitors of SIRT3. A total of 306 SIRT3 inhibitors were identified, with one compound, SDX-437, having an IC(50) of 700 nM with >100-fold selectivity for SIRT3 over SIRT1.
|
Authors | Kaushal Patel, John Sherrill, Milan Mrksich, Michael D Scholle |
Journal | Journal of biomolecular screening
(J Biomol Screen)
Vol. 20
Issue 7
Pg. 842-8
(Aug 2015)
ISSN: 1552-454X [Electronic] United States |
PMID | 26024947
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2015 Society for Laboratory Automation and Screening. |
Chemical References |
- Histone Deacetylase Inhibitors
- Sirtuin 3
|
Topics |
- Acetylation
- Drug Discovery
(methods)
- Enzyme Activation
(drug effects)
- High-Throughput Screening Assays
- Histone Deacetylase Inhibitors
(pharmacology)
- Humans
- Mass Spectrometry
(methods)
- Sirtuin 3
(antagonists & inhibitors)
|